Cristina Queralt

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rafael Rosell, Teresa Morán, Cristina Queralt et al. · New England Journal of Medicine · 2009 · 2.4K citations · Full text

Medicine, Genetics, Oncology +11

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

Miguel Tarón, Yukito Ichinose, Rafael Rosell et al. · Clinical Cancer Research · 2005 · 336 citations

Medicine, Oncology, Pharmacology +17

Brain metastases from lung cancer responding to erlotinib: the importance of<i>EGFR</i>mutation

R. Porta, J.M. Sánchez-Torres, Luis Paz‐Ares et al. · European Respiratory Journal · 2010 · 317 citations · Full text

Medicine, Oncology, Pharmacology +15

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

Miquel Tarón, Rafael Rosell, Enriqueta Felip et al. · Human Molecular Genetics · 2004 · 305 citations · Full text

Medicine, Molecular Genetics, Oncology +17